Immunocore
About:
Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies.
Website: http://immunocore.com
Twitter/X: immunocore
Top Investors: BlackRock, General Atlantic, Eli Lilly, RTW Investments, Bill & Melinda Gates Foundation
Description:
Immunocore is focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The company’s expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems. Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies.
$1.16B
$100M to $500M
Abingdon, Oxfordshire, United Kingdom
2008-01-01
info(AT)immunocore.com
Bent Jakobsen, Nick Cross
251-500
2024-01-30
Public
© 2025 bioDAO.ai